Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iodine I 131 Tositumomab, Etoposide, and Cyclophosphamide Followed by ASCT for Relapsed/Refractory NHL
NCT00073918Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 1999
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iodine i 131 tositumomab in non-Hodgkin lymphoma (NHL), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Progression-Free Survival at 3 years. Started Feb 1999; status: completed.
02
Drugs
iodine i 131 tositumomab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00073918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073918.